Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel and Estramustine in Metastatic Hormone-Refractory Prostate Cancer
NCT00003614Phase 2Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Feb 1999
- Primary completion
- Apr 2005
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and estramustine in prostate cancer (PCa), sponsored by Eastern Cooperative Oncology Group. Primary endpoints: Prostate-Specific Antigen response at 8 weeks, Toxic effects and 4 more. Started Feb 1999; status: completed.
02
Drugs
paclitaxelestramustine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00003614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003614.